AMD

At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of Complement Factor H (CFH), a major genetic risk factor for AMD, and chronic oxidative stress affect the lipid profile of retinal pigment epithelial (RPE) cells.

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

LumiThera's Valeda system offers groundbreaking non-invasive treatment for dry AMD, showing extended vision improvement and safety over 4.5 years.

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

This large database study explored the link between autoimmune problems and AMD.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials for EYP-1901 against aflibercept for the treatment of wet macular degeneration.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Insights from a genome-wide association study identify novel genetic loci

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.